The Biogerontology Research Foundation is leveraging its 10+ years experience on the topics of AI for Longevity Research and Preventive Medicine to support the launch of the UK's first Longevity AI Consortium at King's College London in partnership with Ageing Research at King's (ARK), the APPG for Longevity and Longevity International UK.
The Biogerontology Research Foundation was the main initial donor that provided financial and organisational support to Longevity International UK for the purpose of establishing the All-Party Parliamentary Group for Longevity. As an official partner of the APPG for Longevity, it continues to provide strategic consultation and guidance to contribute to the mission and vision of the APPG, and to help it achieve its goal to add 5 extra years of healthy longevity to all UK citizens by the year 2035.
Longevity Swiss Foundation is a leading Geneva-based Longevity Policy Non-profit and Think Tank working to leverage the national strengths and potentials of Switzerland in order to turn the nation into a world-leading Longevity Hub through the coordinated development of Longevity Politics and Governance, the Longevity BioTech Industry, Preventive Medicine, Precision Health and the emerging Longevity Financial Industry. Leveraging Switzerland’s existing reputation as a hub for independent international policy organizations like the World Economic Forum, the United Nations, UNESCO, the World Health Organization and Others, Swiss Longevity Foundation aims to turn Switzerland into the leading international hub for cross-sector and cross-nation Longevity Development projects and initiatives.
In 2019, to compliment its analytical reports, Aging Analytics Agency released an advanced online Longevity Analytics Platform and database featuring interactive visuals which can transform static analytical reports into dynamic infographics updated in real-time. This platform will enable complex interactions between industry entities and stakeholders to be visualized, filtered, searched and thus more easily understood.
The Biogerontology Research Foundation not only forecast the true dawn of the Longevity Industry years before its mainstream recognition, but was willing to put its reputation at stake with a bold yet precise prediction when no one else saw it coming. Their confidence stems from their reliance on tangible and quantitative predictive metrics, including the use of cross-disciplinary and synergetic analytical tools and frameworks to map the enormous diversity and complexity of the Longevity Industry.
In July 2018, the Biogerontology Research Foundation in coordination with Aging Analytics Agency released the industry analytical report, Longevity Industry in the UK Landscape Overview 2018. 845 pages in length, the report outlined the history, present state and future of the Longevity industry in the UK. This regional case study documented the factors that make the UK well-suited as a global Longevity industry hub, and provided insight on how to foster that potential. To reach its conclusion, the report profiled hundreds of relevant companies and investors, provided an overview of major UK Longevity nonprofits and research labs, and identified major industry trends.
The Biogerontology Research Foundation was the first entity to produce comprehensive Longevity Industry Landscape Overviews in coordination with its strategic partner, Aging Analytics Agency. While the majority of its industry analytical resources have since been taken over by Aging Analytics Agency, the BGRF was pivotal to the initial development of those analytical frameworks.
In 2017 the Biogerontology Research Foundation submitted a joint-proposal with the International Longevity Alliance to the 11th round of revision for the World Health Organization’s International Classification of Diseases system (the main disease classification system used by the majority of developed nations) to classify ageing as a disease based on existing clinical evidence of the causal mechanisms underlying aging and the effectiveness of various interventions in modulating those causal mechanisms. In 2018, the World Health Organization approved the addition of a new extension code for “ageing related” that can be added to any existing disease code. This is the closest any team on the globe has come to classifying ageing as a disease, and gives major financial incentives for drug companies to develop medicines capable of treating the mechanisms of ageing directly.